Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Clinical trial NCT01905657 · COMPLETED
Trial details
- NCT number
- NCT01905657
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-09
- Primary completion
- 2015-09-30
- Enrollment
- 1034
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.